AusBiotech’s virtual showcase during JP Morgan week in January 2021 will seek to highlight the advantages of partnering with Australian life science companies and utilising the R&D Tax Incentive.
Australia has become an attractive location for the conduct of clinical trials in recent years, based on local capability and infrastructure offering companies the ability to attain high-quality clinical data.
Australia’s 43.5% Refundable R&D Tax Offset has further made the country an attractive destination for the conduct of clinical research.
Ausbiotech’s showcase will seek to highlight how Australia’s R&D Tax Incentive offers an attractive environment for companies from around the world to develop their intellectual property in Australia.
When seeking to access Australia’s generous R&D Tax System, international companies should seek advice on their own circumstances, and relevant factors include:
More information is also available on the ATO website.